Ontology highlight
ABSTRACT: Background
Benefit of adding a second-line immunosuppressive drug to glucocorticoids for the treatment of non-associative immune-mediated hemolytic anemia (naIMHA) in dogs has not been defined prospectively.Hypothesis/objectives
Evaluate the effectiveness of different immunosuppressive protocols in naIMHA dogs.Animals
Forty-three client-owned dogs.Methods
Open label, randomized, clinical trial. Dogs were treated with methylprednisolone (M-group), methylprednisolone plus cyclosporine (MC-group) or methylprednisolone plus mycophenolate mofetil (MM-group). Dogs were defined as responders by disappearance of signs of immune-mediated destruction and hematocrit stabilization. Frequency of responders was compared between M-group and combined protocols (MC and MM-gr
SUBMITTER: Agnoli C
PROVIDER: S-EPMC11423485 | biostudies-literature | 2024 Sep-Oct
REPOSITORIES: biostudies-literature